Xeris Biopharma Holdings, Inc. XERS Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s amortization expense related to capitalized debt issuance costs?
- Xeris Biopharma Holdings, Inc. (XERS) reported amortization expense related to capitalized debt issuance costs of $889K in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s amortization expense related to capitalized debt issuance costs changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s amortization expense related to capitalized debt issuance costs increased by 5.3% year-over-year, from $844K to $889K.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s amortization expense related to capitalized debt issuance costs?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s amortization expense related to capitalized debt issuance costs has grown at a 36.2% compound annual growth rate (CAGR), from $961K to $3.31M.